Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer

19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...

Read more →

Flawed evidence underpins approval of new cancer drugs

18 September 2019 - We must raise the bar to ensure real benefits for patients ...

Read more →

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis

18 September 2019 - In this study, the investigators examined the characteristics of randomised controlled trials that supported approval of cancer ...

Read more →

Susan G. Komen Big Data for Breast Cancer Initiative: how patient advocacy organisations can facilitate using big data to improve patient outcomes

12 September 2019 - Integrating different types of data, including electronic health records, imaging data, administrative and claims databases, large data ...

Read more →

U.S. FDA approves supplemental new drug application for Erleada (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer

17 September 2019 - Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of ...

Read more →

Provisional approval of lenvatinib in combination with pembrolizumab for the treatment of advanced endometrial carcinoma

18 September 2019 - The Therapeutic Goods Administration has provisionally approved the use of lenvatinib (Lenvima) in combination with pembrolizumab ...

Read more →

FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma

17 September 2019 - The U.S. FDA is announcing Project Orbis, an initiative of the FDA Oncology Center of Excellence.  ...

Read more →

Lenvima to get benefit as first-line treatment of hepatocellular carcinoma

16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...

Read more →

Seattle Genetics and Astellas announce U.S. FDA grants priority review for enfortumab vedotin biologics license application in locally advanced or metastatic urothelial cancer

16 September 2019 - FDA sets Prescription Drug User Fee action date for 15 March 2020. ...

Read more →

Medexus reports Health Quality Ontario recommends Gliolan for public reimbursement

12 September 2019 - Medexus Pharmaceuticals today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology ...

Read more →

Kiwi cancer survival rates improving at slower rate than comparable countries, study shows

12 September 2019 - New Zealand is near the bottom for cancer survival compared to six other countries with similar ...

Read more →

Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive

10 September 2019 - Dave Roberts is fighting for his life, and his doctor says there is only one option ...

Read more →

Puma Biotechnology announces U.S. FDA acceptance of supplemental new drug application for neratinib to treat HER2-positive metastatic breast cancer

11 September 2019 - Puma Biotechnology announced that the U.S. FDA has accepted for review its supplemental new drug application for ...

Read more →

Merck announces FDA breakthrough therapy designation for investigational therapy tepotinib in patients with metastatic NSCLC with METex14 skipping alterations

11 September 2019 - Investigational oral MET inhibitor has previously received SAKIGAKE ’fast-track’ regulatory designation in Japan. ...

Read more →

Who’s missing from breast cancer trials? Men, says the FDA

9 September 2019 - Men do get breast cancer, but they account for fewer than 1 percent of patients and often ...

Read more →